epatitis C is a viral illness increasing in prevalence and causing considerable burden for the health services across the world. Treatment for this disease has progressed remarkably over the past decade. The purpose of this review is to examine past treatments for hepatitis C and explore the drugs used today to combat this virus.
Bohoslawec O., Trown P., Wills R. (1986) Pharmacokinetics and tissue distribution of recombinant human alpha A, D, A/D(Bgl), and I interferons and mouse alpha-interferon in mice. Journal Interferon Research6: 207-13.
2.
Camma C., Giunta M., Pinzello G., Morabito A., Verderio P., Pagliaro L. (1999) Chronic hepatitis C and interferon alpha: a conventional and cumulative meta-analysis of randomised controlled trials. American Journal ofGastroenterology94: 581-95.
3.
Carreno V. (2002) Present treatment expectations and risks of chronic Hepatitis C. Clinical Microbiology and Infection8: 74-9.
4.
Dusheiko G., Main J., Thomas H., Reichard O., Lee C., Dhillon AH, Rassam S., Fryden A., Reesink H., Bassendine M., Norkrans G., Cuypers T., Lelie N., Telfer P., Watson J., Weegink C., Sillikens P., Weiland O. (1996) Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. Journal ofHepatology25: 591-8.
5.
Fried M., Shiffman M., Reddy K., Smith C., Marinos G., Gonçales FL, Häussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., Yu J. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine347(13): 975-82.
6.
Fattovich G., Zagni I., Ribero M., Castagnetti E., Minola E., Lomonaco L., Scattolini C., Fabris P., Boccia S., Giusti M., Abbati G., Felder M., Rovere P., Redaelli A., Tonon A., Tomba A., Montanari R.,Paternoster C., Distasi M., Fornaciari G., Tositti G., Rizzo C., Suppressa S., Pantalena M., Noventa F., Tagger A. (2004) A randomised trial of prolonged high does interferon plus ribavirin for hepatitis C patient non responders to interferon alone . Journal of Viral Hepatitis11(6): 543-51. tria
7.
Foster G., Goldin R. (2005) Management of chronic viral hepatitis (second edition). Taylor and Francis: London.
8.
Health Protection Agency. (2003) Hepatitis C — general information. 142 See: www.hpa.org.uk/infections/topics_az/hepatitis_c/phlsgenReich_info.htm (accessed 15 April 2005). Wi
9.
Heathcote E., Shiffman M., Cooksley W., Dusheiko G., Lee S., Balart L., Reindollar R., Reddy RK, Wright TL, Lin A., Hoffman J., de Pamphilis J. (2000) Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. New England Journal of Medicine343(23): 1673-80. (ac
10.
Lindsay K., Trepo C., Heintges T., Shiffman M., Gordon S., Hoefs J., Schiff ER, Goodman ZD, Laughlin M., Yao R., Albrecht JK (2001) A randomised, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology34(2): 395-403. 150
11.
Manns M., McHutchinson J., Gordon S., Rustgi V., Shiffman M., Reindollar R., Goodman ZD, Koury K., Ling M., Albrecht JK (2001) Peginterferon alfa-2a plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet358(9286): 958-65. ma
12.
McHutchinson J., Gordon S., Schiff E., Shiffman M., Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S., Albrecht JK (1998) Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis CNew England Journal of Medicine339: 1485-92. O'G
13.
Modi M., Fulton J., Buckmann D., et al. (2000) Clearance of pegylated (40kDa) interferon alfa-2a (PEGASYS) is primarily hepatic. Hepatology32: 371.
14.
National Institute for Clinical Excellence. ( 2004) Interferon alpha (pegylated and non pegylated) and ribavirin in the treatment of chronic hepatitis CNational Institute for Clinical Excellence: London.
15.
Poynard T., Marcellin P., Lee S., Niederau C., Minuk G., Ideo G., Bain V., Heathcote J., Zeuzem S., Trepo C., Albrecht J. (1998) Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet352(9138): 1426-32.
16.
Reichard O., Norkrans G., Fryden A., Braconier J., Sonnerborg A., Wieland O. (1998) Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C . Lancet351: 83-7.
Veldt B., Saracco G., Boyer N., Camma C., Bellobbuono A., Hopf U., Castillo I., Weiland O., Nevens F., Hansen BE, Schalm SW (2005) Long-term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut53: 1504-8.
19.
Wasley A., Alter M. (2000) Epidemiology of hepatitis C: geographical differences and temporal trends. Seminar Liver Disease20: -1-16.
20.
Wilks D., Farrington M., Rubenstein D. (2004) The infectious diseases manual. Blackwell:London.
21.
World Health Organization. (2005) Hepatitis C See: www.who.int/mediacentre/factsheets/fs164/en/ (accessed 15 pril 2005).
22.
Zeuzem S., Fienman S., Rasenack J., Heathcote J., Lai MY, Gane E., 'O'Grady J., Reichen J., Diago M., Lin A., Hoffman J., Brunda MJ (2000) Peginterferon alfa-2a in patients with chronic hepatitis C. New England Journal of Medicine343(23):1666-72.
